Purpose: To evaluate the 1-year efficacy and safety of the 1-piece multifocal intraocular lens (IOL) Clareon PanOptix CNWT. Setting: Department of Ophthalmology, Goethe-University, Frankfurt, Germany. Design: A prospective, single-center, single-arm, interventional study. Methods: Patients with cataract underwent bilateral implantation of a Clareon PanOptix multifocal IOL after phacoemulsification. Examinations included manifest refraction, uncorrected distance visual acuity (UDVA), and corrected distance visual acuity at 4 m, 80 cm, 60 cm, 40 cm, and 30 cm, defocus test, contrast sensitivity under photopic and mesopic conditions and a questionnaire on subjective quality of vision, optical phenomena, and spectacle independence. The primary outcome was visual acuity after 12 months postoperatively. Results: The binocular UDVA was −0.04 ± 0.08 logMAR and at intermediate (80 cm and 60 cm) and near (40 cm and 30 cm) −0.03 ± 0.05 logMAR, −0.04 ± 0.11 logMAR and 0.05 ± 0.11, 0.19 ± 0.12 logMAR, respectively. The binocular distance-corrected defocus curve showed a peak at 0.0 diopter (D) and −2.0 D with −0.07 logMAR and −0.02 logMAR, and between +0.50 D and −3.00 D within 0.10 logMAR. At 12 months, there was no evidence of glistenings in any eye. 24 (89%) participants would choose the IOL again, and 23 of 27 (85%) would recommend the IOL to others. Conclusions: The trifocal Clareon PanOptix IOL provides patients with good visual performance and spectacle independence at all distances without evidence of IOL glistenings.